BlissCo Ecosystem Secures Support from CEO of TallGrass as Advisor to Multi-Billion Dollar Cannabis Wellness Market
July 03 2018 - 9:00AM
- Canadian medical cannabis market expected to grow to $8.7
billion in the first year of legalization
Not for distribution in the U.S. or to
U.S. Newswire Services
BlissCo Cannabis Corp. (CSE:BLIS) (FRA:GQ4B), (“BlissCo”) is
pleased to announce the appointment of Matt Breech, CEO of
TallGrass, to the company’s advisory board. "Mr. Breech brings
decades of success within both the hemp and regulated health
supplement industry. He has tremendous experience in developing and
building distribution channels for health products nationwide. We
believe that Matt will add tremendous value and help BlissCo to
achieve its growth goals,” said Damian Kettlewell, CEO of BlissCo
Cannabis Corp.
Mr. Breech co-founded TallGrass over 20 years ago in 1994. The
company originally sold hemp t-shirts and has since evolved its own
ecosystem into selling natural supplements, superfoods and other
health and wellness products including products under the Botanica
brand. The company distributes to 1,000 wellness stores across
Canada.
“I have a lot of experience working with Health Canada in terms
of regulatory and licensing specifically for natural health
products. It is a unique challenge because before you’re allowed to
take these products to market, the products must comply with a
pre-authorized marketing system, and I have a ton of experience
navigating strict regulation,” said Matt Breech. “We also have an
importer license for every product that we sell and I have a lot of
familiarity with that process. This is another area where I am able
to support Damian in the further development of BlissCo’s global
cannabis ecosystem."
Statista reported that the Canadian market value of medical
cannabis in 2017 was estimated at $4.9-$8.7 billion.
Post-legalization, the market is expected to grow to $8.7 billion
in its first year, with an ancillary market bringing an estimated
$22.6 billion.
“BlissCo is a part of a thriving sector that is just emerging,
and there is already a ton of interest. What really sets BlissCo
apart is that the company has a lot of integrity, it doesn’t
surprise me at all that the company is welcoming such great
entities into its ecosystem. BlissCo is in operation for the right
reasons,” said Breech.
About BlissCo Cannabis Corp.BlissCo Cannabis
Corp. (CSE:BLIS) (FRA:GQ4B) is an ACMPR licensed producer and
future distributor of ultra-premium cannabis. The company sits at
the heart of an international ecosystem and is focused on the
success of its domestic and global partnerships.
BlissCo leverages the latest technology and is continuously
developing its network of top-tier industry experts to drive the
success of its brand and channels, moving premium Canadian cannabis
to local and international markets.
BlissCo is backed by an experienced team that is deeply in tune
and integrated with industry partners and BlissCo's future patients
and customers.
BlissCo began growing medical cannabis in early May 2018 and
applied to Health Canada to amend its ACMPR license to include
cannabis oil production in early June 2018. BlissCo’s cannabis oil
extraction lab room has been built and based on ongoing
communication with Health Canada the company is projected to earn
it’s cannabis oil production license amendment in July 2018.
With its existing capital the company will complete the
outfitting of its top-of-the-line extraction lab which will produce
cannabis oils, tinctures and other high-quality products.
BlissCo will be processing and distributing cannabis purchased
from multiple supply agreements and from cannabis grown at its own
state of the art facility in Metro Vancouver, B.C. BlissCo’s first
supply agreement is with The Supreme Cannabis Company Inc
(TSX.V:FIRE) to purchase 3,000 kilograms of premium whole dried
cannabis flower over two years.
BlissCo is actively exploring brand expansion opportunities in
multiple international markets where medical cannabis is federally
legal. BlissCo has signed an Letter of Intent to export 720
kilograms of medical cannabis annually to a German distribution
partner. BlissCo is having an initial Good Manufacturing Practices
(GMP) facility audit in July 2018 and is projected to earn Eudralex
GMP facility certification in Q4 2018 which will allow the Company
to earn an export certification.
The Company has developed a strategic partnership with Supreme
Cannabis Company Inc. (TSXv: FIRE) whereby Supreme completed a
$3,000,000 strategic equity investment in BlissCo. The investment
gives Supreme a 10% ownership stake in BlissCo.
Learn more: BlissCo.com
On Behalf of the Board of Directors
BLISSCO CANNABIS CORP.
Damian Kettlewell, CEO, Founder & Chair
For further information please contact:
Christina Rao, Investor Relations
1-604-723-7480Christina.Rao@blissco.com
Cautionary Statement
This news release contains certain forward-looking information
and forward-looking statements within the meaning of applicable
securities legislation (collectively “forward-looking statements”).
The use of any of the word “will” and similar expressions are
intended to identify forward-looking statements. These statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results or events to differ materially from
those anticipated in such forward-looking statements. Such
forward-looking statements should not be unduly relied upon. This
news release contains forward-looking statements and assumptions
pertaining to the following: the ability to execute on our
strategic plans and the impact on our future operations, capital
expenditures, receipt of a cannabis oil license and a license to
sell dried cannabis and other objectives. Actual results achieved
may vary from the information provided herein as a result of
numerous known and unknown risks and uncertainties and other
factors. The Company believes the expectations reflected in those
forward-looking statements are reasonable, but no assurance can be
given that these expectations will prove to be correct. The Company
does not undertake to update these forward-looking statements,
except as required by law.
The CSE has in no way passed upon the merits of the proposed
transaction and has neither approved nor disapproved the contents
of this press release.